Floatz logo

Z/E 4-HYDROXY TAMOXIFEN

Estrogen Receptor Positive

Northwestern UniversitySmall moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

77 Active assets in the Estrogen Receptor Positive cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Capivasertib
Imperial College London
Phase 2BB

View all 50 →

Same molecule, other indications

Z/E 4-HYDROXY TAMOXIFEN is also rated in:

ductal breast carcinoma in situDormant
B
Indicative ·
62 / 100
View asset →
Mammographically Dense BreastDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →